Protagonist Therapeutics (NASDAQ:PTGX) Posts Quarterly Earnings Results, Beats Estimates By $0.70 EPS

05 May 2026, 20:22 by Jessica Moore · The Cerbat Gem

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) released its earnings results on Tuesday. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.70, FiscalAI reports. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. The business had revenue of $56.37 million during the quarter, compared to analysts’ expectations of $12.21 million.

Protagonist Therapeutics Stock Down 0.3%

PTGX stock traded down $0.31 during trading hours on Tuesday, hitting $99.21. 392,055 shares of the stock were exchanged, compared to its average volume of 677,162. The company has a 50-day simple moving average of $98.82 and a two-hundred day simple moving average of $89.07. Protagonist Therapeutics has a 12 month low of $41.28 and a 12 month high of $107.84.

Wall Street Analyst Weigh In

PTGX has been the subject of several analyst reports. Citizens Jmp raised their target price on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating and set a $121.00 price target on shares of Protagonist Therapeutics in a report on Wednesday, March 18th. Truist Financial raised their price target on Protagonist Therapeutics from $110.00 to $121.00 and gave the company a “buy” rating in a report on Tuesday, April 14th. HC Wainwright raised their price target on Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a report on Friday, January 30th. Finally, Citigroup raised their price target on Protagonist Therapeutics from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, March 19th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $108.15.

Get Our Latest Analysis on Protagonist Therapeutics

Insider Activity

In related news, CFO Asif Ali sold 24,765 shares of the firm’s stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $104.24, for a total value of $2,581,503.60. Following the transaction, the chief financial officer owned 60,753 shares in the company, valued at approximately $6,332,892.72. This trade represents a 28.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Lewis T. Williams sold 18,000 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $82.42, for a total value of $1,483,560.00. Following the completion of the transaction, the director directly owned 7,825 shares of the company’s stock, valued at approximately $644,936.50. This trade represents a 69.70% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 158,215 shares of company stock worth $15,539,786. Corporate insiders own 4.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC boosted its stake in shares of Protagonist Therapeutics by 140.7% in the 4th quarter. Janus Henderson Group PLC now owns 2,649,981 shares of the company’s stock valued at $231,355,000 after purchasing an additional 1,549,160 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Protagonist Therapeutics by 66.2% in the 4th quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock valued at $276,992,000 after purchasing an additional 1,262,977 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Protagonist Therapeutics in the 3rd quarter valued at approximately $72,114,000. Commodore Capital LP acquired a new stake in shares of Protagonist Therapeutics in the 2nd quarter valued at approximately $59,415,000. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of Protagonist Therapeutics by 218.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,092,262 shares of the company’s stock valued at $60,369,000 after purchasing an additional 748,758 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

(Get Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.